Register | Log in

the chairmans blog

Dr. Robin L. Smith

 

Dr. Robin L. Smith joined the Company as Chairman of its Advisory Board in September 2005 and, effective June 2, 2006, became the Chief Executive Officer and Chairman of the Board.

 

NeoStem

February 6, 2012
0 comments »

Exciting Updates to Neostem.com


As you know, NeoStem has undergone positive transformations this past year. The acquisition of Progenitor Cell Therapy (PCT) and Amorcyte furthers our progress in clinical development significantly. We have updated our website to reflect this change with a wealth of information about our own cell therapeutics. We continue to seek better ways to convey information about the value of NeoStem and our family of companies.

Our site’s “Clinical Development” section, found on the top navigation bar, includes information on our intellectual property portfolio and each of our pipeline product areas: Amorcyte, Athelos, VSELTM Technology and our wound technology. Please read more about NeoStem’s overarching clinical philosophy here as well. The clinical development section includes extensive information on Amorcyte and our most clinically advanced product candidate, AMR-001, which has recently begun patient enrollment for a Phase II trial for the treatment of acute myocardial infarction.

We are excited about updates to our site’s investor section as well. NeoStem has an active conference schedule for 2012 and we list upcoming events where our leadership team will be speaking under the “IR Events” tab. (Conferences attended by PCT are listed at the PCT website.) Our investor portal includes a concise, downloadable corporate profile as well as our updated investor presentation. We have also expanded information on how the acquisition of PCT enables our in-house clinical development, while bringing in revenues from client services.

I look forward to keeping you updated on company news and new website content as it becomes available.



NeoStem (NBS) Stock info

This website contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect management's current expectations, as of the date of these website posts, and involve certain risks and uncertainties. Forward looking statements include statements herein with respect to the successful execution of the Company's business and medical strategy, including with respect to the development of AMR-001 and other cell therapies, about which no assurance can be given. The Company's actual results could differ materially from those anticipated in these forward- looking statements as a result of various factors. Factors that could cause future results to materially differ from the recent results or those projected in forward-looking statements include the "Risk Factors" described in the Company's definitive proxy statement filed with the Securities and Exchange Commission on September 16, 2011 and in the Company's periodic filings with the Securities and Exchange Commission. The Company's further development is highly dependent on future medical and research developments and market acceptance, which is outside its control.
This Blog is official and sanctioned by NeoStem | See Terms of use »


(No commercial advertising involvement of any kind has been solicited or accepted in the authorship of the content within a Chairman's company blog.
Advertising placed on this website is not endorsed or affiliated with authors, the chairmen, CEO's, or their respective companies.)


0 Comments


Be the first to comment!


Log in or create an account to post a comment.